Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML

Inclusion Criteria

• •Age ≥18
• •Relapsed and refractory patients with acute myeloid leukemia via morphology and immunology
• •ECOG：0-2
• •Life expectancy ≥ 3 months
• •Adequate laboratory parameters during the screening period as evidenced by the following:
• •1. Creatinine clearance≥30 mL/min and serum Creatinine ≤ 160µmol/L
• •2. ALT and AST ≤ 3 × upper limit of normal (ULN)
• •3. Able to understand and sign an informed consent form (ICF).
• •4. History of uncontrolled angina pectoris or myocardial infarction within 6 months prior to Screening;
• •5. History of New York Heart Association Class 3 or 4 heart failure;
• •6. Complete left bundle branch block;
• •7. Known history of left ventricular ejection fraction (LVEF) ≤45% or less than the institutional lower limit of normal;
• •Active acute or chronic systemic fungal, bacterial, or viral infection not well controlled by antifungal, antibacterial or antiviral therapy;
• •Suffered from other non-myeloid malignancies within 2 years, except adequately treated non-melanoma skin cancer, curatively treated in-situ disease, or other solid tumors curatively treated with no evidence of disease
• •Females who are pregnant or breastfeeding;
• •Mental disorders that hinder research participation
• •Previous solid organ transplantation (SCT treatment is allowed in advance, but if the patient has GVHD or is still receiving immunosuppression/GVHD treatment, it is not allowed)
• •Any other situation where the investigator believes that the patient should not participate in this trial